ESALF (Eisai Co) Long-Term Debt: $849 Mil (As of Mar. 2026)


ESALF Eisai Co Ltd ESALF
74 GF Score
Price $25.00
GF Value $35.09
Valuation Modestly Undervalued
! 7 Warning Signs
View Full Analysis

What is Eisai Co Long-Term Debt?

Eisai Co ESALF 74 Long-Term Debt is $849 Mil as of Mar. 2026. GuruFocus rates ESALF with a GF Score™ of 74/100 and a GF Value™ of $35.09 (Modestly Undervalued). The stock has 7 warning signs investors should review.

Eisai Co's Long-Term Debt for the quarter that ended in Mar. 2026 was $849 Mil.

Eisai Co's quarterly Long-Term Debt declined from Sep. 2025 ($911 Mil) to Dec. 2025 ($864 Mil) and declined from Dec. 2025 ($864 Mil) to Mar. 2026 ($849 Mil).

Eisai Co's annual Long-Term Debt declined from Mar. 2024 ($900 Mil) to Mar. 2025 ($670 Mil) but then increased from Mar. 2025 ($670 Mil) to Mar. 2026 ($849 Mil).

Eisai Co  (OTCPK:ESALF) Long-Term Debt Explanation

Long-Term Debt is the sum of the carrying values as of the balance sheet date of all long-term debt, which is debt initially having maturities due after one year or beyond the operating cycle, if longer, but excluding the portions thereof scheduled to be repaid within one year or the normal operating cycle, if longer. Long-Term Debt includes notes payable, bonds payable, mortgage loans, convertible debt, subordinated debt and other types of long term debt.

Eisai Co Long-Term Debt Related Terms

Eisai Co Long-Term Debt Historical Data

* Premium members only.

The historical data trend for Eisai Co's Long-Term Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Eisai Co Long-Term Debt Chart

Eisai Co Annual Data
Trend Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24 Mar25 Mar26
Long-Term Debt
Get a 7-Day Free Trial Premium Member Only Premium Member Only 800.26 635.20 899.58 669.76 849.35

Eisai Co Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Long-Term Debt Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 669.76 691.02 911.34 864.35 849.35
ESALF
74GF Score
Eisai Co Ltd ESALF
Long-Term Debt is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
Frequently Asked Questions Learn more about Long-Term Debt →
What does a Long-Term Debt of $849 Mil mean?
Eisai Co (ESALF) has a Long-Term Debt of $849 Mil as of Mar. 2026.
Is Eisai Co's Long-Term Debt too high?
Eisai Co's current Long-Term Debt is $849 Mil. Overall, Eisai Co has a GF Score™ of 74/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Eisai Co's Long-Term Debt compare to ZTS and UTHR?
Eisai Co's Long-Term Debt of $849 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Long-Term Debt for a Drug Manufacturers company?
A good Long-Term Debt depends on the Drug Manufacturers industry context. However, Long-Term Debt should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Long-Term Debt mean?
A high Long-Term Debt can signal that a stock is expensive relative to its fundamentals. Eisai Co's current Long-Term Debt is $849 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Eisai Co stock overvalued right now?
Based on GuruFocus' analysis, Eisai Co (ESALF) is currently considered Modestly Undervalued. The stock's GF Value™ is $35.09, compared to a current price of $25.00 — trading 28.8% below its estimated fair value. The current Long-Term Debt is $849 Mil. Eisai Co's overall GF Score™ is 74/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Long-Term Debt calculated?
Long-Term Debt is calculated from a company's financial statements. For Eisai Co (ESALF), the current Long-Term Debt is $849 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Eisai Co (ESALF) Overvalued in 2026?

Based on GuruFocus' analysis, Eisai Co stock appears to be undervalued. The current stock price of $25.00 is trading 28.8% below its estimated GF Value™ of $35.09. GuruFocus considers Eisai Co to be Modestly Undervalued.

Key valuation signals for ESALF:

  • Long-Term Debt: $849 Mil
  • GF Value™: $35.09 vs. price of $25.00 (28.8% below fair value)
  • GF Score™: 74/100 with 7 warning signs

No single metric tells the full story. See the ESALF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Eisai Co Business Description

Address 4-6-10 Koishikawa, Bunkyo-ku, Tokyo, JPN, 112-8088
Eisai Co Ltd is a specialty and generic drug manufacturing company. The company's business consists of research and development, manufacturing, sales, import, and export of pharmaceuticals. The pharmaceutical business is categorized by region, including East Asia & Global South; Europe, Middle East, Africa, Russia, Oceania (EMEA); Americas; China; and Japan. The company also reports a consumer healthcare business for Japan. The vast majority of the company's revenue is derived from its American pharmaceutical business, followed by its Japanese pharmaceuticals segment. The company utilizes licensing strategies in order to expand its research, development, manufacturing, and marketing capabilities.
74GF Score

Get the complete analysis for ESALF

Long-Term Debt is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$25.00
Price
$35.09
GF Value